BioArctic: Lecanemab receives priority review status in Japan ...Middle East

PR Newswire - News
BioArctic: Lecanemab receives priority review status in Japan
STOCKHOLM, Jan. 30, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™) in Japan has been designated for Priority Review by...

Hence then, the article about bioarctic lecanemab receives priority review status in japan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic: Lecanemab receives priority review status in Japan )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News